Using this approach, we have shown that nasal delivery of LV-CFTR can successfully correct CFTR function in a CF mouse model for up to 12 months after a single dose, and improves survival of the treated animals (Cmielewski et al., 2014). Here, CFTR is linked to cystic fibrosis.